Beijing Huaxia Shengsheng Pharmaceutical

Beijing Huaxia Shengsheng Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on targeting deubiquitinating enzymes (DUBs) within the ubiquitin-proteasome system to treat cancer and metabolic diseases. Its lead program, HX0089, is a highly selective USP1 inhibitor currently in Phase 1 clinical trials for advanced solid tumors, including ovarian and triple-negative breast cancers. Huaxia Shengsheng leverages a proprietary drug discovery platform to identify novel therapeutic candidates with high specificity and potency for previously "undruggable" targets. The company is backed by prominent venture capital firms such as Qiming Venture Partners and HighLight Capital. By focusing on the regulation of protein degradation, Huaxia Shengsheng aims to provide transformative treatments for patients with significant unmet medical needs globally.